These are designed to evaluate the effectiveness of new drugs or antibodies in blocking VISTA's immunosuppressive function.
Immunotherapies including immune checkpoint blocking antibodies have been recognized as the most effective therapies in the treatment of several human cancers. V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology, which is primarily expressed in hematopoietic cells. With advanced and high-end technologies, rich experienced scientists, Creative Biolabs is an excellent service provider in the field of tumor marker assay. After long years ahead to fully comprehend tumor markers, we launch our VISTA assay portfolio service which can be useful for targeted cancer therapy and diagnosis.
VISTA, also known as c10orf54, VSIR, SISP1, B7-H5, PD-1H, DD1α, Gi24, and Dies1, is predominantly expressed within the hematopoietic compartment. It is a 279-amino acid protein with a similar sequence to the B7 family of ligands and receptors, which is structured with a transmembrane domain, an extracellular domain, and a cytoplasmic domain. However, VISTA does not have a classic ITIM/ITAM motif as compared to other B7 co-receptors. Additionally, VISTA is highly conserved between species showing 76% identity between human and mouse, and the highest sequence identity between zebrafish and mouse genomes.
VISTA can act as a ligand expressed on antigen-presenting cells and function as a receptor on T cells. VISTA induces an immunosuppressive environment in multiple cancer types via expression on tumor cells and/or immune cells. The cancers include melanoma, pancreatic cancer, prostate cancer, renal cell carcinoma, non-small cell lung cancer, acute myeloid leukemia, colorectal cancer, ovarian and endometrial cancers, glioma and fibrosarcoma.
Fig.1 Inhibitory immune checkpoint roles of VISTA in anti-cancer immunity. 1, 3
Creative Biolabs offers a portfolio of VISTA-related assays to assist in the development of targeted cancer therapies. These services include:
These are designed to evaluate the effectiveness of new drugs or antibodies in blocking VISTA's immunosuppressive function.
The page mentions various cell-based assays, such as migration, proliferation, invasion, and cytokine assays, which are used to measure the effects of VISTA modulation on cell behavior and function.
The company provides custom services for specific research needs related to VISTA.
Speak with our experts today to receive a customized solution and quote.
This review examines the critical role of the immune checkpoint protein VISTA in mediating immune evasion in cancer. The authors summarize that VISTA is a potent negative regulator of both adaptive and innate immunity. It suppresses T-cell activation and promotes the function of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). The review highlights that VISTA is frequently upregulated after anti-PD-1/PD-L1 therapy, making it a key mechanism of adaptive resistance. Preclinical evidence shows that blocking VISTA, especially with anti-PD-1/PD-L1, can overcome this resistance and enhance anti-tumor immunity.
Fig.2 Anti-VISTA blockade reverses resistance to anti-PD-1/PD-L1 treatment. 2, 3
Creative Biolabs' VISTA assay portfolio service stands out due to a combination of deep scientific expertise and state-of-the-art technology. We have a profound understanding of VISTA biology and the complexities of immune checkpoint research, which allows us to provide accurate, reliable, and high-quality data. This commitment to scientific excellence ensures that our clients receive the most relevant information to support their therapeutic development. When you choose Creative Biolabs, you gain a partner dedicated to delivering personalized service and expert guidance, accelerating your path to success in the biopharmaceutical industry.
To explore a tailored partnership and discover how our expertise can accelerate your project's success, contact us for a detailed proposal today.
A1: VISTA and PD-1 act through non-redundant pathways. Targeting VISTA can be a powerful strategy to overcome resistance to PD-1/PD-L1 therapies, especially since VISTA expression can increase after PD-1 blockade.
A2: As a less-explored checkpoint compared to PD-1, VISTA's biology can be complex. Its dual role as a ligand and receptor and its ability to function in acidic tumor microenvironments require specialized assay conditions.
A3: We specialize in custom service offerings. If your project has a unique requirement, our scientific team is ready to consult with you to design a bespoke assay protocol. We are committed to finding a solution that precisely fits your research needs.
Creative Biolabs offers comprehensive services to combat cancer resistance. Our solutions leverage the latest technology to provide personalized and targeted treatment options, helping customers overcome the significant challenges of resistance to standard therapies.
Learn More →Creative Biolabs offers a wide range of tumor metabolic characterization services. Our expertise in tumor metabolism allows us to provide services like metabolic pathway analysis, multi-omics platforms, and cellular metabolism assays.
Learn More →Ready to advance your cancer immunotherapy research with our VISTA assay portfolio service? Our team of experts is ready to discuss your project and provide a customized solution.
Contact Our Team for More Information and to Discuss Your Project.
References